Based on the news articles, the sentiment for Divi's Labs is mixed for the current week.

Notable events:

* Divi's Labs shares jump 5% due to a US court staying FDA approval for Entresto drug, which is a positive event.
* The company is among the top gainers in the Nifty Pharma index, which has reached a record high and outperformed the Nifty 50 with over 10% growth in one month, indicating a positive trend.
* However, Divi's Labs is set to be replaced by Trent and Bharat Electronics in the Nifty 50 index from September 30, which could be seen as a negative event.

Overall, the news tone is neutral for Divi's Labs. While the company has seen some positive developments, such as the jump in shares due to the US court's decision and its inclusion in the top gainers in the Nifty Pharma index, it is also facing the negative event of being replaced in the Nifty 50 index.

Historical analysis suggests that the impact of similar news on the stock price has been varied. In some cases, the stock has seen a positive impact, such as when pharma stocks gained due to the approval of COVID pill Molnupiravir, while in other cases, the impact has been negative, such as when the company's shares fell due to a court's decision.